Humanigen, Inc.

Humaneered® Monoclonal Antibodies to Neutralize Cytokine Storm Induced by SARS-CoV-2 (COVID-19), CAR-T, and GvHD.

[Humanigen, Inc. @humanigen]

Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress

Full Story: https://t.co/mXv7opGRkr

@humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Medical

[Humanigen, Inc. @humanigen]

Humanigen was honored to present progress from the PREACH-M trial evaluating lenzilumab in CMML today at AACR in Orlando, FL

#HGEN

[Humanigen, Inc. @humanigen]

Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia

Full Story: https://t.co/ByY1OIT5Ew

@humanigen $HGEN #HGEN #Humanigen

[Humanigen, Inc. @humanigen]

Humanigen Reports Third Quarter 2022 Financial Results

Full Story: https://t.co/gVw8fgOh88

@humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Earnings #QuarterlyResults #Results #NASDAQ #Investing

[Humanigen, Inc. @humanigen]

Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

Full Story: https://t.co/vyAVi4Uzug

@humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing

[Humanigen, Inc. @humanigen]

Humanigen Announces Retention of SC&H Capital as Financial Advisor

Full Story: https://t.co/ULCXpdDj3f

@humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing

[Humanigen, Inc. @humanigen]

Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML

Full Story: https://t.co/lLWnY3ljoe

@humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing

[Humanigen, Inc. @humanigen]

Humanigen to Participate in H.C. Wainwright and Cantor Investor Conferences in September 2022

Full Story: https://t.co/AWQffU5CDE

@humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing

[Humanigen, Inc. @humanigen]

@Luke96278769 @NIH This really is question for NIAID/NIH about its studies, but it would appear the distinction is TLD is available for BET-B and not yet available for BET-A and BET-C. Full results to be published by NIAID/NIH in a peer-reviewed journal at a future date.

[Humanigen, Inc. @humanigen]

Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones

Full Story: https://t.co/7YMf5Iv3P3

@humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Pharmaceuticals #Biotechnology #Medical #NASDAQ #Investing

[Humanigen, Inc. @humanigen]

A press release with some additional detail is also available on our investor relations website

https://t.co/AMrYXd3hBT

[Humanigen, Inc. @humanigen]

Humanigen is pleased to announce peer-reviewed publication in Thorax supporting early treatment of hospitalized COVID-19 patients with lenzilumab guided by C-Reactive Protein (CRP)

https://t.co/t1rZFvkFO4

[Humanigen, Inc. @humanigen]

NIH/NIAID Locks ACTIV-5/BET-B Database

HGEN received notice today from the National Institute of Allergy and Infectious Diseases (NIAID) that they have completed database lock for the Big Effect Trial of lenzilumab

https://t.co/M5p6eZhpkO

[Humanigen, Inc. @humanigen]

Watch HGEN Annual Meeting at 1pm EDT today. Access the meeting in listen-only mode via the Guest tab.
https://t.co/biYPFhk7Bf

[Humanigen, Inc. @humanigen]

@Ashu21637893 As we have indicated in the corporate presentation available on #HGEN IR website, we expect top-line data from the NIH ACTIV-5/BET-B study of #lenzilumab in 2Q22

https://t.co/iRNPClpX4m

[Humanigen, Inc. @humanigen]

We believe that COVID-19 will become a serious endemic disease and will continue to impact society, healthcare systems and patients for years to come.

[Tom Wenseleers now @twenseleers.bsky.social @TWenseleers]

The BA.4 & BA.5 Omicron subvariant-driven increase of new confirmed Covid cases in South Africa gives a good idea of what the endemic equilibrium will look like: a significant wave every 6 months with significant mortality & morbidity. 🧵

[Tom Wenseleers now @twenseleers.bsky.social @TWenseleers]

It's as if medicine agencies still haven't come to terms with the fact that SARS-CoV2 evolves ca 2.5x faster than the fastest evolving influenza strain. And that vaccine updates would have to be made twice as fast then as for influenza... https://t.co/GUMhvfdazY

[Humanigen, Inc. @humanigen]

The ability of the virus to mutate, in a manner that confers the potential for immune escape, highlights the importance of treatments that target the host's immune response rather than the virus itself. #variantagnostic

[Tom Wenseleers now @twenseleers.bsky.social @TWenseleers]

The growth rate advantage of BA.4 & BA.5 over BA.2 is similar than that of BA.2 over BA.1 and of Delta over Alpha. But with caveat that BA.4 & BA.5 carry 2 mutations in the spike receptor binding domain that are predicted to confer some immune escape. https://t.co/fvrCtkcMjF

[Humanigen, Inc. @humanigen]

FDA halts the use of GSK's Covid-19 drug completely as BA.2 subvariant blankets the country – Endpoints News. Time for a variant agnostic mAB? #lenzilumab https://t.co/bLvjG9TYVz

[P1 /human @stolgic]

$HGEN New LIVE-AIR commentary published in ACP journals https://t.co/pJ9uQv1zJP